Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibody response to COVID-19 vaccination in immunocompromised risk groups at Adrz hospital
NL-OMON50794Not yet recruiting
- Sponsor
- Interne Geneeskunde
- Start
- Mar 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Open-label trial of tozinameran and elasomeran in coronavirus disease 2019 (COVID-19) (6 arms), sponsored by Interne Geneeskunde. Primary endpoints: Vaccine efficacy and Antibody response. Planned start Mar 2021; status: not yet recruiting.
02
Drugs
tozinameranelasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON50794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50794.